Clinical Trial Update: PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating tau PET imaging with tracer [18F]-PI-2620 in frontotemporal dementia and atypical Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Frontotemporal Dementia

Drugs mentioned

• [18F]PI-2620 (PI-2620)

Snippet

Sponsor: University of Pennsylvania | Conditions: Frontotemporal Lobar Degeneration, Alzheimer Disease | Phase 3 | Status: RECRUITING